Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2001
10/30/2001US6309825 Analytical and therapeutic agents
10/30/2001US6309820 Polypeptides having a functional domain of interest and methods of identifying and using same
10/30/2001US6309671 Stable glassy state powder formulations
10/30/2001US6309669 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
10/30/2001US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
10/30/2001US6309659 Reverse phase connective tissue repair composition
10/30/2001US6309651 A method of inhibiting, moderating or diagnosing pseudomonas aeruginosa infection is disclosed.
10/30/2001US6309648 Induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of b. pertussis, b. parapertussis, and b. bronchiseptica when administered to a human or animal host.
10/30/2001US6309645 A method of suppressing an immune response in a mammal.
10/30/2001US6309644 Parasitic nematode transglutaminase proteins and uses thereof
10/30/2001US6309643 Diagnosis and treatment of inflammatory bowel disease using microbial antigens.
10/30/2001US6309640 Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
10/30/2001US6309639 Administering an antibody to a protein component or to a carbohydrate-protein component of p-selectin glycoprotein ligand, the glycoprotein ligand comprising a fucosylated sialylated glycoprotein containing sialyl lewis x antigen
10/30/2001US6309638 Netrins
10/30/2001US6309636 Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
10/30/2001US6309634 Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)
10/30/2001US6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
10/30/2001US6309632 For reducing hiv viral load and treating aids by administering granulocyte-macrophage colony stimulating factor (gm-csf).
10/30/2001US6309381 Use of human growth hormone to treat acute myocardial infarction
10/30/2001CA2227308C Dna sequence coding for a polypeptide which enhances virus infection of host insects
10/30/2001CA2170143C Cell death regulator
10/30/2001CA2093643C Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
10/30/2001CA2052375C Parathyroid hormone derivatives
10/30/2001CA2047843C Method and product for the treatment of gastric disease
10/30/2001CA2002833C Interferon-gamma binding proteins
10/30/2001CA1341311C Transduced fibroblasts and uses therefor
10/28/2001CA2345569A1 Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
10/27/2001CA2345444A1 Novel therapeutic processes and useful compositions therefor
10/27/2001CA2345180A1 Methods of treating obesity using a neurotensin receptor ligand
10/26/2001CA2319149A1 Medicament for treatment of duchenne muscular dystrophy
10/25/2001WO2001079557A2 Gtp-binding protein useful in treatment and detection of cancer
10/25/2001WO2001079539A2 Method for using transfectable constructions from luciferase and from the promotor of the human period 1 gene for identifying novel active substances that influence the day/night rhythm and sleep
10/25/2001WO2001079525A2 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001WO2001079510A1 Materials and methods relating to immune responses to fusion proteins
10/25/2001WO2001079508A1 A novel polypeptide, a human mitochondrial carrier protein 9 and the polynucleotide encoding the polypeptide
10/25/2001WO2001079506A2 Treatment of ocular neovascularization and related diseases
10/25/2001WO2001079505A2 INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
10/25/2001WO2001079501A2 Nucleic acid coding for at least one raf partial sequence with a mekk1 binding site
10/25/2001WO2001079496A2 Ligand for herpes simplex virus entry mediator and methods of use
10/25/2001WO2001079495A1 Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer
10/25/2001WO2001079494A1 Agonist antibodies
10/25/2001WO2001079491A1 A novel polypeptide-human chloride channel protein 12 and the polynucleotide encoding said polypeptide
10/25/2001WO2001079489A2 39228, a human alcohol dehydrogenase and uses therefor
10/25/2001WO2001079487A2 Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079479A2 Methods for selective targeting
10/25/2001WO2001079478A1 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening inhibitors of these factors and the inhibitors
10/25/2001WO2001079474A1 Method for modification of proteins by transglutaminase
10/25/2001WO2001079473A2 21953, a human prolyl oligopeptidase family member and uses thereof
10/25/2001WO2001079469A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
10/25/2001WO2001079468A2 Drug metabolizing enzymes
10/25/2001WO2001079466A2 Regulation of human epithin-like serine protease
10/25/2001WO2001079465A2 Nucleic acids encoding polypeptides having haloperoxidase activity
10/25/2001WO2001079462A2 Nucleic acids encoding polypeptides having haloperoxidase activity
10/25/2001WO2001079461A2 Polypeptides having haloperoxidase activity
10/25/2001WO2001079459A2 Polypeptides having haloperoxidase activity
10/25/2001WO2001079455A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN
10/25/2001WO2001079449A2 Novel nucleic acids and polypeptides
10/25/2001WO2001079447A2 Novel bone marrow nucleic acids and polypeptides
10/25/2001WO2001079446A2 Materials and methods relating to lipid metabolism
10/25/2001WO2001079445A2 Pluripotent cells comprising allogenic nucleus and mitochondria
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079437A2 Novel polypeptide a human cell differential transcriptional factor 14 and polynucleotide encoding it
10/25/2001WO2001079431A2 A novel polypeptide, a human pathway 15 protein with the huntingtine protein and the polynucleotide encoding the polypeptide
10/25/2001WO2001079299A1 Enhancement of antibody-mediated immune responses
10/25/2001WO2001079296A1 Humar emr2, a g-protein coupled receptor from the egf-tm7 family
10/25/2001WO2001079293A2 Human cadherin molecules and uses therefor
10/25/2001WO2001079291A2 Secreted proteins
10/25/2001WO2001079288A2 Cytokine uses; compositions; methods
10/25/2001WO2001079287A2 Steatosis-modulating factors and uses thereof
10/25/2001WO2001079286A2 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001WO2001079285A1 Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
10/25/2001WO2001079284A2 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001WO2001079283A1 Modulating cell survival by modulating huntingtin function
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079281A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001WO2001079280A1 A novel polypeptide - human ccr4 protein 16 and the polynucleotide encoding said polypeptide
10/25/2001WO2001079279A1 A novel polypeptide-homo tnf receptor-associated factors 16 and polynucleotide encoding said polypeptide
10/25/2001WO2001079278A1 Lactobacillus johnsonii bacteriocin, active against helicobacter pylori
10/25/2001WO2001079276A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
10/25/2001WO2001079274A2 Tuberculosis antigens and methods of use thereof
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079270A2 Migraine and vasodilation treatment
10/25/2001WO2001079268A2 A glycopeptide and preparation thereof
10/25/2001WO2001079267A2 A glycopeptide and preparation thereof
10/25/2001WO2001079263A1 Peptide derivatives and medicinal compositions
10/25/2001WO2001079262A1 Pyrazinone and pyridinone derivatives as thrombin inhibitors
10/25/2001WO2001079261A1 Tetrahydro-azepinone derivatives as thrombin inhibitors
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079254A1 Novel nucleic acids and polypeptides
10/25/2001WO2001079253A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001WO2001079246A2 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
10/25/2001WO2001079216A2 Polyamide nucleic acid derivatives, agents and methods for producing them
10/25/2001WO2001079195A2 Pyridine and pyrazine derivatives as thrombin inhibitors
10/25/2001WO2001079193A2 Substituted hydrazinyl heteroaromatic inhibitors of thrombin
10/25/2001WO2001079167A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001WO2001078894A2 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
1 ... 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 ... 3163